

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-227) BATIRAXCEPT

PRONUNCIATION ba tir' ax sept

THERAPEUTIC CLAIM Treatment of ovarian cancer

CHEMICAL NAMES

1. 8-202-Tyrosine-protein kinase receptor UFO [14-serine,54-valine,69-glycine,74-alanine,109-arginine] (human) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin G1 (human γ 1-chain C region C-terminal fragment), dimer (Source: CAS)

2. Human Tyrosine-protein kinase receptor UFO (AXL oncogene, EC=2.7.10.1) (8-202) modified fragment [$G^{14}>S(7)$, $A^{54}>V(47)$, $D^{69}>G(62)$, $V^{74}>A(67)$, $G^{109}>R(102)$] (1-195) fusion protein with tetraglycylseryl linker (196-200) fusion protein with IGHG1*03 Fc modified fragment {[hinge del-(1-5)>(201-210)], CH3[K¹⁰⁷>del(427)]} (201-426),dimer (206-206':209-209')-bisdisulfide, produced in CHO cell, glycoform alfa

STRUCTURAL FORMULA

Sequence (dimer) X & X'

EESPFVSNPG	NITGARGLTG	TLRCQLQVQG	EPPEVHWLRD	GQILELVDST	50
QTQVPLGEDE	QGDWIVASQL	RITSLQLSDT	GQYQCLVFLG	HQTFVSPQGY	100
VRLEGLPYFL	EEPEDRTVAA	NTPFNLSCQA	QGPPEPVDLL	WLQDAVPLAT	150
APGHGPQRSL	HVPGLNKTSS	FSCEAHNAKG	VTTSRATIT	VLPQGGGGGS	200
DKTHTCPCPC	APELLGGPSV	FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	250
PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	300
CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	350
GFYPDSIAVE	WESNGQPENN	YKTTTPVLDS	DGSFFLYSKL	TVDKSRWQQG	400
NVFSQVMHE	ALHNHYTQKS	LSLSPG			426

Disulfide bridges location

24-85	24'-85'	128-173	128'-173'	206-206'
209-209'	241-301	241'-301'	347-405	347'-405'

Glycosylation sites (N)

Asn-11	Asn-11'	Asn-125	Asn-125'	Asn-166	Asn-166'
Asn-277	Asn-277'				

MOLECULAR FORMULA $C_{4166}H_{6450}N_{1130}O_{1290}S_{26}$ (non glycosylated)

MOLECULAR WEIGHT 93.84 kDa (non glycosylated)

TRADEMARK None as yet

SPONSOR Aravive, Inc.

CODE DESIGNATIONS AVB-S6-500, AVB-500, S6-500c, Ruga-S6, Aravive-S6

CAS REGISTRY NUMBER 2268717-61-7

UNII

B6840JH4EB

WHO NUMBER

11391

gbk